We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?
- Authors
Antoñanzas, F.; Juárez-Castelló, C. A.; Rodríguez-Ibeas, R.
- Abstract
The article reports on the drug approval process of European Medicines Agency. Topics discussed include analysis of a large amount of data generated by clinical trials; three different approaches to deal with new drug development issues such as accelerated assessment, conditional marketing authorization, and compassionate use; and impact of Brexit on the same.
- Subjects
DRUG approval; EUROPEAN Medicines Agency; CLINICAL trials; DATA analysis; DRUG marketing
- Publication
European Journal of Health Economics, 2018, Vol 19, Issue 7, p905
- ISSN
1618-7598
- Publication type
editorial
- DOI
10.1007/s10198-017-0944-0